Literature DB >> 1945038

Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat.

B Lannes1, G Micheletti, J M Warter, E Kempf, G Di Scala.   

Abstract

The effects of N-methyl-D-aspartate (NMDA) antagonist ketamine given acutely or chronically were investigated on dopamine-related motor functions. Acute administration (15, 22.5, 30 mg/kg, i.p.) reversed the catalepsy induced by a dopamine (DA) antagonist (haloperidol, 0.25 mg/kg, i.p.) in the rat. When given orally and chronically (15 mg/kg per day) during at least 60 days, no alteration of spontaneous motor behaviour was observed, but the responsiveness to a DA agonist (apomorphine, 0.125 or 0.25 mg/kg s.c.) and to haloperidol was enhanced, suggesting an hypersensitivity of the DA receptors following the chronic blockade of NMDA receptors. However, following prolonged administration of ketamine there were no alteration of DA levels and turnover. Taken together these results suggest that the mechanisms involved in this DA receptor hypersensitivity should be postsynaptic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1945038     DOI: 10.1016/0304-3940(91)90255-r

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments.

Authors:  A R Owolabi; M A Akanmu; O E Ukponmwan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-12       Impact factor: 3.000

2.  Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.

Authors:  Ignasi Oliveras; Ana Sánchez-González; Daniel Sampedro-Viana; Maria Antonietta Piludu; Cristóbal Río-Alamos; Osvaldo Giorgi; Maria G Corda; Susana Aznar; Javier González-Maeso; Cristina Gerbolés; Gloria Blázquez; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel
Journal:  Psychopharmacology (Berl)       Date:  2017-02-02       Impact factor: 4.530

3.  Lack of persistent effects of ketamine in rodent models of depression.

Authors:  Piotr Popik; Tomasz Kos; Magdalena Sowa-Kućma; Gabriel Nowak
Journal:  Psychopharmacology (Berl)       Date:  2008-05-07       Impact factor: 4.530

Review 4.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

Review 5.  The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.

Authors:  Herbert Y Meltzer; Masakuni Horiguchi; Bill W Massey
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

6.  Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Authors:  Adem Can; Panos Zanos; Ruin Moaddel; Hye Jin Kang; Katinia S S Dossou; Irving W Wainer; Joseph F Cheer; Douglas O Frost; Xi-Ping Huang; Todd D Gould
Journal:  J Pharmacol Exp Ther       Date:  2016-07-28       Impact factor: 4.030

7.  The monoaminergic pathways and inhibition of monoamine transporters interfere with the antidepressive-like behavior of ketamine.

Authors:  Glauce Socorro de Barros Viana; Cecilia Coelho Xavier; Eduardo Mulato do Vale; Maria Janice Pereira Lopes; Viviane de Jesus Alves; Roberta de Oliveira Costa; Kelly Rose Tavares Neves
Journal:  IBRO Rep       Date:  2017-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.